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Providencia Joyanes,1 Antonio Doménech-Sánchez,3 and Vicente Javier Benedí3
Department of Microbiology, School of Medicine, University of Seville,1 and University Hospital V. Macarena,2 Seville, and
Laboratory of Microbiology, IMEDEA (CSIC-UIB), Universitat de les Illes Balears, Palma de Mallorca,3 Spain
Received 28 January 2002/Returned for modification 18 May 2002/Accepted 8 September 2002
The relationships between porin deficiency, active efflux of fluoroquinolones, and extended-spectrum -lac-
tamase (ESBL) production were determined for 53 clinical isolates of Klebsiella pneumoniae. Thirty-two
ESBL-positive strains (including 22 strains expressing porins and 10 strains lacking porins) and 21 ESBL-
negative strains were evaluated. Active efflux of norfloxacin was defined as a >50% increase in the accumu-
lation of norfloxacin in the presence of carbonyl cyanide m-chlorophenylhydrazone (CCCP) in comparison with
the corresponding basal value in the absence of CCCP. The quinolone resistance-determining regions of both
gyrA and parC from 13 strains, representing all isolates with different porin profiles and with or without active
efflux, were determined. Porin loss was significantly more common among ESBL-positive strains (10 of 32
[31.2%]) than among ESBL-negative strains (0 of 2 [0%]) (P < 0.01). Active efflux was observed in 7 of 10
(70%) strains lacking porins and in 4 of 43 (9.3%) strains producing porins (P < 0.001). The 11 strains showing
active efflux corresponded to 3 of 21 (14.3%) ESBL-negative strains and 8 of 32 (25.5%) ESBL-positive strains
(P > 0.05). Basal values of norfloxacin accumulation were higher in strains lacking active efflux than in those
that had this mechanism (P < 0.05). In the absence of topoisomerase changes, the contribution of either porin
loss or active efflux to fluoroquinolone resistance in K. pneumoniae was negligible. It is concluded that among
K. pneumoniae strains of clinical origin, porin loss was observed only in those producing ESBL, and that a
significant number of porin-deficient strains also expressed active efflux of norfloxacin. In terms of fluoro-
quinolone resistance, both mechanisms are significant only in the presence of topoisomerase modifications.
Klebsiella pneumoniae strains producing extended-spectrum
-lactamases (ESBL) are more frequently resistant to fluoro-
quinolones than K. pneumoniae strains lacking these enzymes
(22). ESBL-producing K. pneumoniae strains intermediate or
resistant to ciprofloxacin contain gyrA mutations, alone or
combined with parC mutations (4, 5, 6, 12, 25). It is also
possible that the plasmid coding for the ESBL, or an additional
plasmid within the same strain, may contain a qnr-like deter-
minant as described for organisms expressing plasmid-medi-
ated AmpC type enzymes (14). Qnr is responsible for low-level
resistance to quinolones and favors increased resistance to
these drugs (14).
An alternative explanation for -lactam–fluoroquinolone
coresistance in ESBL-producing K. pneumoniae is a decrease
in the permeability of the outer membrane to both classes of
agents because of porin alterations. Non-ESBL-producing
strains usually express the two major porins (OmpK35 and
OmpK36) of the species, while ESBL-producing strains com-
monly express either only one of these (normally OmpK36) or
no porin (9). Porin loss in ESBL-producing K. pneumoniae
causes resistance to cefoxitin and increased resistance or de-
creased susceptibility to all oxyimino cephalosporins, zwitteri-
onic cephalosporins, and -lactam–-lactamase combinations
(1, 11, 13). Loss of these channels causes a moderate (two- to
fourfold) increase in the level of resistance to fluoroquinolones
when modifications of topoisomerase II (alone or combined
with changes in topoisomerase IV) are present (5, 12). The
direct role of either OmpK35 or OmpK36 in the resistance of
K. pneumoniae strains to fluoroquinolones and to -lactams
has been demonstrated. Expression of either porin from a
vector containing wild-type ompK35 or ompK36 in strains lack-
ing both OmpK35 and OmpK36 decreases the level of resis-
tance (1, 13; A. Doménech-Sánchez, S. Hernández-Allés, L.
Martínez-Martínez, and V. J. Benedí, Abstr. 38th Intersci.
Conf. Antimicrob. Agents Chemother., abstr. C186, 1998).
In addition to decreased permeability, it is possible that
active efflux also contributes to fluoroquinolone resistance in
K. pneumoniae. A few clinical isolates of ESBL-producing K.
pneumoniae that have porin deficiencies and express energy-
dependent efflux of fluoroquinolones have been described (5,
12). In Escherichia coli and Salmonella enterica serovar Typhi-
murium, pumps for efflux of quinolones may also export -lac-
tams from the cells (19–21). Expression of the ramA locus from
K. pneumoniae in E. coli causes resistance to norfloxacin and is
related to both increased efflux of antimicrobial agents and loss
of the OmpF porin (8). These activities are similar to those
caused by the transcriptional activator marA of E. coli, which
contributes to multiple antimicrobial resistance by increasing
the activity of the AcrAB-TolC efflux system and by decreasing
the permeability of the outer membrane due to increased tran-
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scription of micF, a transcriptional repressor of the porin gene
ompF (3, 21).
The objectives of this study were (i) to determine the activ-
ities of several quinolones against clinical isolates of K. pneu-
moniae with characterized mechanisms of resistance, (ii) to
establish whether porin loss and active efflux of fluoroquino-
lones are more frequently observed in clinical isolates of
K. pneumoniae producing ESBL than in those not producing
ESBL, (iii) to evaluate the potential relationship between
porin expression and active efflux, and (iv) to analyze the roles
of porin loss and active efflux in the quinolone resistance levels
of clinical strains of K. pneumoniae with or without mutations
in topoisomerase-encoding genes.
MATERIALS AND METHODS
Bacterial strains. Fifty-three K. pneumoniae strains of clinical origin were
studied. Three groups of strains were selected for evaluation in the present study:
(i) 10 clonally unrelated strains of ESBL-producing K. pneumoniae deficient in
both OmpK35 and OmpK36 expression (see below) isolated either in our labo-
ratory or in another geographical zone (porin-deficient strains), (ii) 22 clonally
unrelated ESBL-producing strains expressing porins in their outer membranes
(these include 3 strains clonally related to those of the previous group), and (iii)
21 clonally unrelated non-ESBL-producing K. pneumoniae strains. We lack, and
are not aware of, ESBL-negative clinical strains of K. pneumoniae deficient in the
two major porins of the species.
The 32 ESBL-producing K. pneumoniae strains included strains C1 and C2
(14), strain CSUB10R (1), and strains MCQ-102, MCQ-121, and MCQ-122,
kindly provided by P. Bradford (2); strains GAJ-3, GAJ-18, and GAJ-20, kindly
provided by G. A. Jacoby (G. A. Jacoby, P. Han, M. Alvarez, and F. Tenover,
Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C40, 1995); six
strains (LTZ205, LTZ-3273, RL-1, RL-2, RL-5, and RL-5X) from Greece, kindly
provided by L. Tzouvelekis (24); and 17 strains from the University Hospital
Virgen Macarena, Seville, Spain, isolated between 1996 and 1998. ESBL-defi-
cient organisms were isolated between 1996 and 1998 at the University Hospital
Virgen Macarena, Seville, Spain (HUS strains; n  19) or the Ciudad Sanitaria
Universitaria de Bellvitge, Barcelona, Spain (CSUB strains; 2 strains from the
same patient).
Organisms were identified with the API 20E system (bioMérieux, La Balme
Les Grottes, France) and maintained in tryptic soy broth (Difco, Detroit, Mich.)
with 20% glycerol (Difco) at 80°C until use.
Clonal relationship of strains was determined by pulsed-field gel electrophore-
sis (PFGE) of genomic DNA digested with SmaI as previously described (1). All
ESBL-deficient strains from Seville represented different clones, while the two
CSUB strains showed the same PFGE pattern (data not shown).
E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as
control strains in susceptibility testing assays.
Susceptibility testing. MICs of antimicrobial agents were determined by mi-
crodilution according to NCCLS guidelines (17). The following agents were
tested: ciprofloxacin (Bayer, Leverkusen, Germany), clinafloxacin (Parke-Davis,
Ann Arbor, Mich.), moxifloxacin (Bayer), nalidixic acid (Sigma, Madrid, Spain),
norfloxacin (Sigma), pefloxacin (Rhône-Poulenc, St. Antoine, France), pipe-
midic acid (Sigma), and trovafloxacin (Pfizer, Groton, Conn.). When available,
clinical categories were determined according to NCCLS guidelines (18).
ESBL production was detected by microdilution, and strains were considered
ESBL positive when clavulanic acid (fixed concentration, 2 g/ml) caused a
8-fold reduction of the MICs of ceftazidime, cefotaxime, and/or aztreonam.
Analysis of OMPs. Bacterial cells grown to logarithmic phase were lysed by
sonication. Outer membrane proteins (OMPs) were obtained after treatment of
cell membranes recovered by ultracentrifugation with sodium lauryl-sarcosynate
(2%; Sigma) and subsequent ultracentrifugation. OMP profiles were determined
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 11% acryl-
amide, 0.345% bisacrylamide, and 0.1% sodium dodecyl sulfate in the running
gel. After electrophoresis, proteins were stained with Coomassie brilliant blue
(Sigma) (11).
Accumulation of norfloxacin. Bacteria grown in nutrient broth were suspended
in phosphate-buffered saline (PBS) (ca. 0.650 mg of bacteria [dry weight]/ml),
incubated with 10 g of norfloxacin/ml at 37°C for 30 min, and centrifuged
through a silicone oil barrier (, 1.029 g/cm3) to eliminate extracellular quino-
lone. For the 11 strains of 53 evaluated that did not traverse the silicon oil layer,
extracellular norfloxacin was eliminated by a wash with 1 ml of PBS (at 12,800 
g and 4°C for 1 min) (16). The cell pellet obtained by either method was placed
in 2 ml of 0.1 M glycine-HCl buffer (pH 3.0), vortexed, and centrifuged for 5 min
at 12,800  g. The amount of norfloxacin in the supernatant (basal accumula-
tion) was measured spectrophotometrically (12). The effect of the energy inhib-
itor carbonyl cyanide m-chlorophenylhydrazone (CCCP) (0.1 mM) was evalu-
ated in parallel by addition of CCCP to bacterial suspensions 10 min after the
addition of norfloxacin and reincubation of the cells for 20 min. Experiments
were done in duplicate on three different days. An organism was considered to
express energy-dependent accumulation of norfloxacin when CCCP enhanced
basal accumulation by at least 50%, a threshold which corresponds to twice the
standard deviation of the mean basal accumulation for the strains tested.
Analysis of mutations in topoisomerase-encoding genes. Thirteen strains, rep-
resentative of all possible combinations among level of susceptibility, porin
profile, and expression of active efflux, were tested. Alterations in the GyrA
subunit of DNA gyrase and the ParC subunit of topoisomerase IV were deter-
mined by sequencing the quinolone resistance-determining regions (QRDRs) of
the gryA and parC genes by use of primers previously described by Deguchi et al.
(4).
Statistical analyses. Relationships between ESBL production, loss of porins,
and expression of active efflux were determined by the chi-square test and were
considered statistically significant at a P of 0.05. Norfloxacin accumulation
values were expressed as means 	 standard deviations, and differences among
groups were compared by analysis of variance, which was used to assess statistical
significance at a P of 0.05.
RESULTS
Susceptibility testing. Twenty-two out of the 53 strains stud-
ied were susceptible to nalidixic acid (NAL-S), and 31 were
resistant to nalidixic acid (NAL-R; MICs, in all cases, were
64 g/ml). NAL-S strains included 13 strains producing
ESBL and 9 strains not producing ESBL. NAL-R strains in-
cluded 19 and 12 organisms producing and not producing
ESBL, respectively (Fig. 1).
All NAL-S strains were inhibited by pipemidic acid at 8 g/
ml, and all NAL-R strains were inhibited by 16 g of pipe-
midic acid/ml, except in one case (MIC of pipemidic acid,
4 g/ml). All NAL-S strains were inhibited by 0.06 g of
ciprofloxacin or clinafloxacin/ml. MICs of both norfloxacin and
pefloxacin for NAL-S strains were 0.06 g/ml (16 strains)
and 0.125 g/ml (6 strains), while MICs of trovafloxacin and
moxifloxacin for NAL-S strains were 0.06 g/ml (20 strains),
0.125 g/ml (1 strain), and 0.25 g/ml (1 strain). The MIC90s
(MICs at which 90% of isolates were inhibited) of norfloxacin
and pefloxacin for NAL-S strains were 0.125 g/ml, and
MIC90s of the remaining four fluoroquinolones for this group
of strains were 0.06 g/ml.
Distributions of MICs of fluoroquinolones against NAL-R
strains are shown in Table 1. It can be observed that MICs of
norfloxacin and pefloxacin for NAL-R strains were always
0.5 g/ml, and those of ciprofloxacin were always 0.125 g/
ml. On the other hand, MICs of clinafloxacin were 2 g/ml
for all 32 NAL-R strains. As shown in Table 1, MIC90s of all
fluoroquinolones for which the NCCLS establishes break-
points fall within the resistant category.
Analysis of OMPs. All 53 strains tested produced an OmpA-
like protein of about 32 kDa. All 21 ESBL-negative strains
(either NAL-S or NAL-R) produced OMPs in the range of 35
to 37 kDa, compatible with the hypothesis that they are porins.
Among ESBL-producing strains, porin expression was ob-
served in 22 strains (68.8%), and not in the remaining 10
strains (31.2%) (Fig. 1). These data indicate that porin loss is
significantly (P  0.01) more frequent among ESBL-producing
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strains. Representative results of OMP analysis are presented
in Fig. 2.
Accumulation of norfloxacin. In a set of independent exper-
iments in which the absolute value of norfloxacin accumulation
was determined for 10 strains (representative of the different
accumulation models observed) by both the silicon oil method
and the PBS washing method, lower absolute values were ob-
tained with the latter method, but the percentages of increase
in norfloxacin accumulation caused by CCCP determined by
the two methods were not significantly different (data not
shown). For this reason we have considered the percentage of
increase in norfloxacin accumulation caused by CCCP to be an
indicator of efflux, regardless of whether this was determined
by the silicon oil method (42 strains) or the PBS washing
method (11 strains).
Only for 11 of 53 strains did CCCP enhance the concentra-
tion of accumulated norfloxacin more than 50% over the cor-
responding basal accumulation value. Active efflux was sig-
nificantly more frequent (P  0.001) among porin-deficient
strains (7 of 10 [70.0%]) than among porin-producing strains
(4 of 43 [9.3%]). A higher percentage of strains showing active
efflux of norfloxacin was noted among ESBL-positive strains
(8 of 32 [25.0%]) than among ESBL-negative strains (3 of 21
[14.3%]), but this difference was not statistically significant
(P 
 0.05). For seven strains the increase in norfloxacin accu-
mulation due to CCCP was 210 to 275%, and for four strains
the increase was 56 to 75%. Addition of CCCP caused a 50%
increase in the accumulation of norfloxacin in 19 strains: 1 to
20% in 6 strains, 11 to 20% in 8 strains, and 31 to 49% in 5
strains. Interestingly, CCCP caused decreased norfloxacin ac-
cumulation in the remaining 23 strains: the percentages of
decrease were 62% (n  1), 36% (n  1), 20 to 26% (n  3),
10 to 19% (n  10), and 1 to 9% (n  8).
Among the 42 strains for which accumulation of norfloxacin
was assayed by the silicon oil method, basal accumulation val-
FIG. 1. Relationship between susceptibility to nalidixic acid, ESBL-production, porin expression, and active efflux of norfloxacin (AEN) in 53
clinical isolates of K. pneumoniae.
TABLE 1. Distribution of MICs, MIC50s, and MIC90s of six
fluoroquinolones against 31 NAL-R strains of K. pneumoniae
Drug
No. of strains inhibited at the




0.06 0.125 0.25 0.5 1 2 4 8 16 32 64
Ciprofloxacin 1 1 5 1 5 6 4 4 2 2 4 32
Clinafloxacin 10 2 4 9 4 2 0.25 1
Moxifloxacin 4 3 6 6 8 2 1 1 2 8
Norfloxacin 4 4 2 2 5 8 2 4 8 64
Pefloxacin 4 2 3 3 6 8 2 3 8 32
Trovafloxacin 2 3 7 4 8 4 2 1 2 8
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ues were higher in strains lacking active efflux of norfloxacin
than in strains showing active efflux of norfloxacin (P  0.05).
No such comparison was attempted for strains assayed by the
centrifugation method because none of them expressed active
efflux as previously defined.
Accumulation of norfloxacin in strains lacking active efflux
after cells were treated with CCCP ranged from 219 to 589
ng/mg of bacteria (dry weight), while the corresponding range
in active-efflux-positive strains was 273 to 505 ng/mg of bacteria
(dry weight) (P 
 0.05).
Norfloxacin accumulation in 11 strains with active efflux of
norfloxacin is presented according to porin expression pattern
in Table 2. Norfloxacin accumulation in three strains deficient
in porin expression and lacking active efflux of norfloxacin
(Table 3) was not significantly different (P 
 0.05) from that
observed for strains that do not express active efflux but ex-
press porins.
Target modifications. As shown in Table 4, the QRDRs of
both GyrA and ParC of the four NAL-S strains evaluated were
identical to the sequences reported for K. pneumoniae strain
ATCC 13833: codons 83 and 87 of gyrA coded for Ser and Asp,
respectively, while codons 78, 80, and 84 of parC coded for Gly,
Ser, and Glu, respectively. The same results were obtained for
two strains with low-level resistance to nalidixic acid: MICs of
nalidixic acid were 64 and 256 g/ml for strains HUS 33-99 and
HUS 298-98, respectively. All strains with high-level resistance
to nalidixic acid (MIC  1,024 g/ml) had mutations at gyrA,
either alone or combined with mutations in parC. No cases of
mutation in parC were observed in the absence of mutations in
gyrA. Mutations in codon 83 of gyrA caused a change from Ser
to either Phe or Tyr, while mutations in codon 87 caused a
change from Asp to either Tyr or Asn. Mutations in parC
caused changes at position 78 (Gly to Cys), 80 (Ser to Arg), or
84 (Glu to Gly). There were no obvious relationships between
the types of mutations in topoisomerase genes and the level of
resistance to fluoroquinolones.
Norfloxacin accumulation and porin expression in pairs of
clonally related strains (presenting the same PFGE pattern)
are presented in Table 5.
DISCUSSION
Resistance to fluoroquinolones in K. pneumoniae is more
commonly found among ESBL-producing strains than among
non-ESBL producers (22). In this study the possible associa-
tions between altered permeability, active efflux of norfloxacin,
and ESBL production in clinical isolates of K. pneumoniae
were evaluated. Additionally, topoisomerase changes were also
determined for some strains in order to evaluate in more detail
the relevance of the above-mentioned mechanisms. The pos-
FIG. 2. OMP profiles of ESBL-producing (A) and non-ESBL-producing (B) K. pneumoniae strains. (A) Lane 2, strain HUS 76-96; lane 3, strain
HUS 56-96; lane 4, strain HUS 33-96; lane 5, strain HUS 71-96; lane 6, strain HUS 20-97; lane 7, strain HUS 91-96. (B) Lane 9, strain RL-1; lane
10, strain RL-2; lane 11, strain RL-5X; lane 12, strain RL-5b; lane 13, strain GAJ-3; lane 14, strain HUS 8-98. Lanes 1 and 8, molecular size markers
(in kilodaltons). Symbols: open circle, LamB-like protein; arrowhead, porin; solid circle, OmpA-like protein.
TABLE 2. Accumulation of norfloxacin without and with 100 M
CCCP in 11 strains of K. pneumoniae showing energy-dependent
accumulation of norfloxacin and expressing porins or not
Strain
Accumulation of norfloxacina
(ng/mg of bacteria [dry wt])
Basalb With CCCPc
Porin deficient
RL-1 103 	 25 273 	 53
RL-5b 128 	 25 352 	 34
LTZ-3273 253 	 41 437 	 59
C1 247 	 61 505 	 55
C2 220 	 35 410 	 81
CSUB10R 188 	 19 429 	 50
MCQ-122 269 	 39 430 	 32
Porin expressing
CSUB-61A 298 	 22 445 	 13
HUS 71-96 245 	 59 436 	 73
HUS 298-98 182 	 80 417 	 56
GAJ-18 161 	 63 331 	 32
a Data are means 	 standard deviations from three independent duplicate
experiments.
b Tested in the absence of CCCP.
c Tested in the presence of 100 M CCCP.
TABLE 3. Accumulation of norfloxacin without and with CCCP in
three strains of K. pneumoniae deficient in porins and lacking
energy-dependent accumulation of norfloxacin
Strain
Accumulation of norfloxacina
(ng/mg of bacteria [dry wt])
Basal With 100 mM CCCP
RL-2 441 	 80 387 	 90
GAJ-3 386 	 33 386 	 33
MCQ-102 454 	 119 372 	 88
a Data are expressed as means 	 standard deviations from three independent
duplicate experiments.
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sible protection of DNA gyrase by a Qnr-like protein (14, 23)
has been ruled out in a parallel study (data not shown). Figure
1 shows the distribution of the 53 strains tested in this study
according to quinolone susceptibility, ESBL production, porin
expression, and active efflux expression.
Our results indicate that in clinical isolates of K. pneumo-
niae, porin loss is more frequent among ESBL-positive than
among ESBL-negative strains and that in this organism active
efflux of norfloxacin occurs more commonly among porin-de-
ficient strains. Although the percentage of strains showing ac-
tive efflux was higher among ESBL-positive than among
ESBL-negative isolates, this trend was not statistically signifi-
cant. It is possible that the method we used for detecting active
efflux is not sensitive enough and/or that the breakpoint for
defining it (a 50% increase in accumulation in the presence of
CCCP) is too strict (note that for five strains, CCCP enhanced
accumulation by 31 to 49%). It would be interesting to evaluate
a larger number of strains, to measure accumulation of other
substrates, or to use other methodological approaches (an as-
say with radiolabeled fluoroquinolone, or immunological de-
TABLE 4. Mutations at the QRDRs of gyrA and parC in 13 clinical strains of K. pneumoniae
Strain
Presence or absencea of: MIC Mutationd
ESBL Porin Efflux NALb CIPc
GyrA ParC
Ser83 Asp87 Gly78 Ser80 Glu84
CSUB-61A    0.5 0.004 — — — — —
CSUB-61B    0.5 0.008 — — — — —
HUS 76-96    2 0.06 — — — — —
LTZ-3273    16 0.06 — — — — —
HUS 33-96    64 0.125 — — — — —
HUS 298-98    256 0.5 — — — — —
C2    
1,024 0.5 Phe — — — —
MCQ-102 e   
1,024 0.5 Tyr — — — —
C1    
1,024 4 Tyr — — —
HUS 22-97    
1,024 4 Phe Tyr — — Gly
HUS 20-97    
1,024 8 Phe Tyr — — Gly
MCQ-121 e   
1,024 64 Phe Asn Cys Arg —
MCQ-122 e   
1,024 128 Phe Asn Cys Arg —
a , presence; , absence.
b NAL, nalidixic acid.
c CIP, ciprofloxacin.
d —, no change with respect to wild-type sequence.
e AmpC type -lactamase producer.
TABLE 5. Accumulation of norfloxacin without and with CCCP in five pairs of clonally related K. pneumoniae strains








ESBL Porin Basal With CCCP GyrA ParC NALd CIPe NOR f CLINg
CUSB-61A 1   570 	 27 219 	 78 wt wt 0.5 0.004 0.03 0.06
CUSB-61B 1   298 	 22 445 	 13 wt wt 0.5 0.008 0.06 0.06
RL-5X 2   470 	 25 409 	 79 wt wt 8 0.06 0.25 0.06
RL-2 2   441 	 80 387 	 90 wt wt 4 0.06 0.5 0.06
LB2h 3   286 	 24 385 	 65 Ser83Tyr wt 
1,024 0.5 2 0.06
LB4h 3   116 	 21 263 	 38 Ser83Tyr wt 
1,024 1 4 0.06
CSUB10S 4   313 	 6 ND Ser83Phe wt 
1,024 0.5 1 0.06
CSUB10R 4   188 	 19 429 	 50 Ser83Phe wt 
1,024 4 8 0.06
MCQ-121 5 i  434 	 53 405 	 79 Ser83Phe, Asp87Asn Gly78Cys, Ser80Arg 
1,024 64 256 1
MCQ-122 5 i  298 	 22 445 	 13 Ser83Phe, Asp87Asn Gly78Cys, Ser80Arg 
1,024 128 
256 2
a , presence; , absence.
b Basal, without CCCP; with CCCP, in the presence of 100 M CCCP. Data are means 	 standard deviations from three independent duplicate experiments. ND,
not determined.
c wt, wild type.




h Data for LB2 and LB4 have been reported previously (11) and are included for comparison.
i Also producing the AmpC type ACT-1 -lactamase.
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tection of the efflux system proteins) to confirm that active
efflux is not related to ESBL production.
The data in Table 1 indicate the existence of cross-resistance
to nalidixic acid and fluoroquinolones in K. pneumoniae, al-
though the effects of the mechanisms of resistance are different
for different compounds. Clinafloxacin was, in terms of
MIC90s, the most active fluoroquinolone of those tested here,
followed by moxifloxacin, trovafloxacin, ciprofloxacin, pefloxa-
cin, and norfloxacin.
K. pneumoniae ATCC 13833 and many other quinolone-
susceptible clinical isolates contain serine instead of threonine
at position 83, as previously reported for K. pneumonaie M5a1
(7). A recent report has shown that Klebsiella oxytoca 13182
contains threonine (25). Our data with four NAL-S strains also
indicate that serine is normally found at position 83 of GyrA in
K. pneumoniae, while Phe or Tyr is present in K. pneumoniae
strains with high-level resistance to NAL. Changes in GyrA
Asp87 to Tyr or to Asp have been observed in our NAL-R
strains. These have also been the most frequent substitutions
found in other studies (4, 5, 6, 25). Mutations in parC (coding
for Ser80Arg and Glu84Gly) were observed in four out of five
NAL-R and ciprofloxacin-resistant strains. In the two clonally
related strains MCQ-121 and MCQ-122, a mutation in parC
that is responsible for a Gly78Cys change and that has not been
rpeviously reported for K. pneumoniae was noted. The rele-
vance of this change awaits further study.
This study and previous studies (4, 5, 6, 12) indicate that the
levels of resistance to nalidixic acid and fluoroquinolones in
clinical isolates of K. pneumoniae are not completely explained
by changes in the QRDRs of gyrA and parC (Table 4; compare
strain HUS76-96 with strain LTZ-3273 and strain MCQ-102
with strain C1).
Strains CSUB10R and LB4 are deficient in porins, contain a
GyrA change, and in addition exhibit energy-dependent accu-
mulation of fluoroquinolones (11, 12). On the other hand, the
clonally related strains CSUB10S and LB2 express OmpK36
and do not show energy-dependent accumulation of fluoro-
quinolones. This suggests a link between the loss of the two
porins and expression of energy-dependent accumulation of
fluoroquinolones in clinical isolates of K. pneumoniae. To eval-
uate this hypothesis, norfloxacin accumulation was determined
in a collection of unrelated porin-deficient strains and, for
comparison, in a representative number of porin-expressing
strains (either producing or not producing ESBL).
We measured norfloxacin accumulation by using a fluoro-
metric assay, eliminating extracellular fluoroquinolone by cen-
trifugation through a silicon oil barrier or by washing cells with
PBS. In this study, lower norfloxacin accumulation was ob-
tained when the PBS washing method instead of the silicon oil
method was used, in agreement with previous reports (16;
unpublished data). Although the actual reasons for these dif-
ferences have not yet been satisfactorily explained, the ap-
proach we used of defining active efflux as a ratio of accumu-
lation in the presence of CCCP to accumulation in the absence
of CCCP allows comparison of the results obtained by these
two methods.
In some of the strains we studied, CCCP caused decreased
(rather than increased) accumulation of norfloxacin. It can be
hypothesized that, in these strains, CCCP induces the expres-
sion of one or more efflux pumps also involved in fluoroquin-
olone elimination, but further work is needed to clarify these
results.
Seven of the 11 strains expressing active efflux of norfloxacin
were porin deficient, while among the 10 porin-deficient strains
evaluated, 7 expressed energy-dependent accumulation of fluo-
roquinolones (Fig. 1).
Accumulations (either in the absence or in the presence of
CCCP) in the seven strains expressing efflux of fluoroquino-
lones and lacking porins were not statistically different (P 
0.05) from those in four strains expressing energy-dependent
accumulation of fluoroquinolones and producing porins (Table
2), while accumulations in strains lacking active efflux were not
different (P 
 0.05) for strains expressing or lacking porins
(Table 3). This suggests that when the major porins of K.
pneumoniae are lost, norfloxacin (and perhaps other fluoro-
quinolones) may still accumulate in the cell by other means
and that decreased accumulation depends more on elimination
by active efflux than on decreased permeability by porin loss.
Further studies are required to deduce the independent roles
of active efflux and of loss of porins in the final amount of
norfloxacin accumulated in strains expressing both mecha-
nisms.
In a previous study it was shown that when other mecha-
nisms of resistance are absent, loss of porins in K. pneumoniae
C3 does not contribute significantly to quinolone resistance
(10). In this study we have observed, for strains CSUB-61A and
CSUB-61B, that expression of energy-dependent accumulation
of fluoroquinolones alone does not significantly increase the
level of resistance (Table 5). When both porin loss and active
efflux are present in the same organism that has a topoisom-
erase change(s), a moderate increase in the level of fluoro-
quinolone resistance is observed. This has been described pre-
viously for strains LB2 and LB4 (11) and for strains CSUB10S
and CSUB10R (1) and has been observed here for strains
MCQ-121 and MCQ-122 (with double mutations in both gyrA
and parC). This indicates that multiple target mutations are
much more important than nonspecific mechanisms for quin-
olone resistance, but the latter may be a critical step favoring
the emergence of mutants with altered targets.
K. pneumoniae may express a basal efflux of fluoroquinolo-
nes, as already observed for E. coli and other enterobacteria.
The wide range of norfloxacin accumulation in the strains we
studied may reflect variation in undefined factors that deter-
mine binding of the drug to the cell but may also represent
variable expression of active efflux in different organisms. In E.
coli, AcrAB-TolC is the more clinically relevant efflux system,
since it is involved in the elimination of fluoroquinolones,
-lactams, and other antimicrobial agents (15, 20). Preliminary
results (data not shown) indicate that K. pneumoniae contains
an AcrAB homologue. New studies are in progress to evaluate
the importance of AcrAB-TolC and other efflux systems in the
strains included in this report.
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